Ila Tamaskar

865 total citations
18 papers, 684 citations indexed

About

Ila Tamaskar is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Ila Tamaskar has authored 18 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Ila Tamaskar's work include Renal cell carcinoma treatment (9 papers), Renal and related cancers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Ila Tamaskar is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Renal and related cancers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Ila Tamaskar collaborates with scholars based in United States. Ila Tamaskar's co-authors include Ronald M. Bukowski, Brian I. Rini, Robert Dreicer, Laura S. Wood, S. Sethu K. Reddy, Paul Elson, Tarek Mekhail, L. Wood, J. Garcia and Роберто Пили and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ila Tamaskar

16 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ila Tamaskar United States	11	448	356	254	200	115	18	684
Zafeiris Zafeiriou United Kingdom	13	536 1.2×	158 0.4×	422 1.7×	345 1.7×	24 0.2×	31	873
Raphael Brandão Moreira United States	11	369 0.8×	106 0.3×	504 2.0×	99 0.5×	52 0.5×	30	719
Annamaria Guazzi Italy	15	215 0.5×	144 0.4×	311 1.2×	168 0.8×	53 0.5×	35	597
A.H. Honkoop Netherlands	10	107 0.2×	135 0.4×	298 1.2×	211 1.1×	47 0.4×	20	577
Ji Zhou China	16	174 0.4×	129 0.4×	292 1.1×	91 0.5×	131 1.1×	39	621
Ann Michelini United States	10	200 0.4×	186 0.5×	721 2.8×	133 0.7×	505 4.4×	15	1.0k
Nathalie Théou–Anton France	14	322 0.7×	127 0.4×	362 1.4×	79 0.4×	138 1.2×	28	666
J. Luz Tovar García Colombia	7	140 0.3×	145 0.4×	275 1.1×	68 0.3×	34 0.3×	8	591
J.M. Sánchez-Torres Spain	13	428 1.0×	150 0.4×	614 2.4×	104 0.5×	39 0.3×	21	772
Edem Agamah United States	12	149 0.3×	151 0.4×	176 0.7×	119 0.6×	87 0.8×	16	560

Countries citing papers authored by Ila Tamaskar

Since Specialization

Citations

This map shows the geographic impact of Ila Tamaskar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ila Tamaskar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ila Tamaskar more than expected).

Fields of papers citing papers by Ila Tamaskar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ila Tamaskar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ila Tamaskar. The network helps show where Ila Tamaskar may publish in the future.

Co-authorship network of co-authors of Ila Tamaskar

This figure shows the co-authorship network connecting the top 25 collaborators of Ila Tamaskar. A scholar is included among the top collaborators of Ila Tamaskar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ila Tamaskar. Ila Tamaskar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Li, Gen, et al.. (2023). Validation of the Plasmic Score and Development of a Novel Predictive Model for Thrombotic Thrombocytopenic Purpura: Exploring Socioeconomic Disparities and Outcomes. Blood. 142(Supplement 1). 2632–2632.

Sivak, Edward D., et al.. (2022). A 62-Year-Old Woman With Nodules, Cysts, and Activated Bone Marrow. CHEST Journal. 161(3). e175–e180.

Tamaskar, Ila, et al.. (2021). Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. The Oncologist. 26(5). e827–e830. 15 indexed citations

Tamaskar, Ila, et al.. (2011). Resistance to angiogenesis inhibitors in renal cell carcinoma.. PubMed. 9(2). 101–10. 28 indexed citations

Sharma, Neelesh, et al.. (2010). KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.. PubMed. 1(2). 90–6. 10 indexed citations

Tamaskar, Ila & Роберто Пили. (2009). Update on novel agents in renal cell carcinoma. Expert Review of Anticancer Therapy. 9(12). 1817–1827. 15 indexed citations

Tamaskar, Ila, Tarek Mekhail, Robert Dreicer, et al.. (2008). Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease. Investigational New Drugs. 26(6). 553–559. 9 indexed citations

Tamaskar, Ila & Ming Zhou. (2008). Clinical implications of caveolins in malignancy and their potential as therapeutic targets. Current Oncology Reports. 10(2). 101–106. 4 indexed citations

Rini, Brian I., Ila Tamaskar, Laura S. Wood, et al.. (2007). Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute. 99(1). 81–83. 283 indexed citations

10.

Tamaskar, Ila, Toni K. Choueiri, Linda Sercia, et al.. (2007). Differential expression of caveolin‐1 in renal neoplasms. Cancer. 110(4). 776–782. 21 indexed citations

11.

Tamaskar, Ila, Jorge A. García, Paul Elson, et al.. (2007). Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy. The Journal of Urology. 179(1). 81–86. 114 indexed citations

12.

Tamaskar, Ila, Ronald M. Bukowski, Paul Elson, et al.. (2007). Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Annals of Oncology. 19(2). 265–268. 114 indexed citations

13.

Tamaskar, Ila, J. Garcia, Robert Dreicer, et al.. (2007). Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. Journal of Clinical Oncology. 25(18_suppl). 5048–5048. 5 indexed citations

14.

Golshayan, Ali, Toni K. Choueiri, Paul Elson, et al.. (2007). Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy. Journal of Clinical Oncology. 25(18_suppl). 5046–5046. 4 indexed citations

15.

Tamaskar, Ila, et al.. (2006). The clinical picture. A woman with aplastic anemia and a rash.. Cleveland Clinic Journal of Medicine. 73(12). 1088–1090. 1 indexed citations

16.

Tamaskar, Ila, Philip Shaheen, L. Wood, et al.. (2006). Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. Journal of Clinical Oncology. 24(18_suppl). 4597–4597. 21 indexed citations

17.

Shaheen, Philip, Ila Tamaskar, Brian I. Rini, et al.. (2006). Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Journal of Clinical Oncology. 24(18_suppl). 4605–4605. 20 indexed citations

18.

Tamaskar, Ila & Keyvan Ravakhah. (2004). Spontaneous Bacterial Peritonitis with Pasteurella Multocida in Cirrhosis: Case Report and Review of Literature. Southern Medical Journal. 97(11). 1113–1115. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact